Moyano B, Clemente A, Marín-Jiménez I, Martorell A
Servicio de Dermatología, Hospital Punta de Europa, Algeciras, Cádiz, España.
Servicio de Gastroenterología, Hospital General Universitario Gregorio Marañón, Madrid, España.
Actas Dermosifiliogr. 2016 Sep;107 Suppl 2:43-50. doi: 10.1016/S0001-7310(17)30008-X.
The recent approval of adalimumab as the first treatment to be approved for the management of hidradenitis suppurativa has represented a before and after in the control of this chronic inflammatory disease. Given the inflammatory burden of this cutaneous disease, in the last few years hidradenitis suppurativa has been compared with inflammatory bowel disease, particularly with Crohn disease, to the point of considering hidradenitis suppurativa as "Crohn disease of the skin". These two chronic inflammatory diseases show sufficient similarities to consider whether treatment response based on the inflammatory load could also be similar. The present article aims to analyse the efficacy of adalimumab in hidradenitis suppurativa in comparison with a truly comparable disease, Crohn disease, with a view to evaluating therapeutic response rates and to drawing conclusions on the therapeutic success obtained in this disabling cutaneous disease.
阿达木单抗最近被批准作为首个用于治疗化脓性汗腺炎的药物，这在这种慢性炎症性疾病的控制方面具有里程碑意义。鉴于这种皮肤病的炎症负担，在过去几年中，化脓性汗腺炎一直与炎症性肠病，特别是克罗恩病相比较，以至于将化脓性汗腺炎视为“皮肤克罗恩病”。这两种慢性炎症性疾病有足够的相似之处，值得探讨基于炎症负荷的治疗反应是否也相似。本文旨在分析阿达木单抗在化脓性汗腺炎中的疗效，并与真正具有可比性的疾病——克罗恩病进行比较，以评估治疗反应率，并就这种致残性皮肤病所取得的治疗成功得出结论。
